Vitamins C and E and beta carotene, either individually or in combination, do not appear to reduce the risk of cardiovascular events or death among women at high risk for heart disease, according to a report in the August 13/27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
A reanalysis of the data used in a previous analysis of the drug Rosiglitazone — marketed by GlaxoSmithKoine as Avandia — using different statistical models suggests that the earlier methodology may have resulted in inflated risk estimates.
Researchers at the University of Pennsylvania School of Medicine have discovered that a group of liver enzymes called proprotein convertases (PCs) may be the key to raising levels of good cholesterol (HDL-C). The pathway by which these proteins are able to achieve an increase in HDL cholesterol involves another enzyme that normally degrades HDL-C, and was also discovered at Penn.
Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug. 7th print issue of Circulation: Journal of the American Heart Association.
The American College of Cardiology and the American Heart Association have jointly released revised Guidelines for the Management of Patients with Unstable Angina (UA)/Non-ST- Elevation Myocardial Infarction (NSTEMI).
Australia’s largest study of eating habits has found that traditional Mediterranean foods may prevent cardiovascular diseases such as heart attack and stroke. A 10 year study into the dietary patterns of about 40,000 Melburnians has just been published in the latest American Journal of Clinical Nutrition.
Following a joint meeting of the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development underscores its position that ACTOS (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.
Heart attack patients as far as 150 miles away from a 24-hour emergency heart care center were able to receive treatment for blocked arteries within or faster than current recommended time frames, according to a study published in Circulation: Journal of the American Heart Association.
Heart attack patients received lifesaving treatment quickly when hospitals and communities used an integrated, rapid transfer system to get patients to a facility equipped to perform artery-opening procedures, according to a report in Circulation: Journal of the American Heart Association.
The following summarizes GlaxoSmithKline?s [NYSE: GSK] presentation of data on Avandia? (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007.